Crescendo Biologics Extends IP Protection for Transgenic Mouse Technology

Cambridge, UK. 8th August 2012 – Crescendo Biologics Limited (Crescendo) today announces it has gained further patent protection (covering the generation of mice in which the endogenous mouse immunoglobulin heavy chain locus has been functionally deleted).

The European Patent office has granted patent EP1597382 (inventors: Brüggemann et al), the first European grant for this patent family for Crescendo

Crescendo has also received Notice of Allowance of US13/081,035 (a continuation of its granted patent US 7,932,431) which provides further cover for the heavy chain knock out approach in the US.

The knock-out of endogenous mouse heavy chain antibody expression is key to Crescendo's generation of its proprietary 'triple knockout' mice that have the immunoglobulin heavy chain (IgH), kappa light chain and lambda light chain loci all functionally deleted. Crescendo believes generating mice completely devoid of endogenous antibody polypeptides has application across the spectrum of transgenic mouse platforms for antibody generation.

The triple knock out mouse is core to Crescendo's own V_H antibody fragment platform which generates human heavy-chain only antibodies in transgenic mice as a source of V_H fragments to generate novel, high value products for in-house development and strategic partnering.

Contacts

Mike Romanos/Amanda Bettison
Crescendo Biologics
Tel: +44 (0) 1223 497140
Email: mromanos/abettison@crescendobiologics.com

Chris Gardner
Citigate Dewe Rogerson
Tel: +44 (0)207 638 9571
Email: chris.gardner@citigatedr.co.uk

About Crescendo Biologics Ltd

Crescendo Biologics is building a pipeline of novel medicines based on its highly innovative V_H antibody fragment platform through both in-house development and strategic partnerships. Crescendo's proprietary V_H technology produces human heavy chain-only antibodies in transgenic mice providing a unique source of candidate-quality V_H fragments that have matured *in vivo* to have high affinity, stability and solubility, and do not require humanisation. V_H fragments are the smallest antibody fragments that retain binding affinity and specificity offering the potential to generate novel products with improved drug-like properties and able to address unmet medical needs.

Crescendo Biologics

Crescendo's technologies were invented by scientists at the Babraham Institute, Cambridge (UK). It has raised funding totalling £7.7 million from an investment consortium led by Sofinnova Partners with participation from Babraham Bioscience Technologies, Avlar BioVentures, Aitua and the Rainbow Seed Fund.

www.crescendobiologics.com